Physician profile
Fernando Silva
NPI 1528286960
$54,391.50
in general payments reported to CMS, 2019-2025
33 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $9,853 · 2021: $4,818 · 2022: $6,178 · 2023: $1,221 · 2024: $2,416 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,485 · Consulting Fee: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,484.91 |
| Consulting Fee | $1,417.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,422.64 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Horizon Therapeutics Plc | $13,281.42 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $2,585.74 | 2019-2025 | Tremfya, Simponi Aria |
| Globus Medical, INC. | $2,383.20 | 2019-2020 | |
| Amgen INC. | $2,089.68 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $602.59 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $555.88 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $513.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $503.43 | 2023-2025 | Saphnelo |
| Pfizer INC. | $433.14 | 2019-2025 | |
| Genentech USA, INC. | $340.87 | 2019-2025 | Gazyva |
| Centinel Spine, LLC | $297.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.19 | 2019-2025 | Ofev |
| Ucb, INC. | $256.19 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $214.40 | 2019-2024 | Taltz |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $107.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $70.20 | 2023-2024 | Opsumit |
| Depuy Synthes Sales INC. | $64.34 | 2019-2024 | Teligen |
| Fresenius Kabi USA, LLC | $56.74 | 2024 | Idacio, Tyenne |
| Sandoz INC. | $39.98 | 2024-2025 | Jubbonti, Hyrimoz |
| Merck Sharp & Dohme LLC | $38.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $38.03 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $32.52 | 2025 | |
| Sobi, INC | $20.67 | 2024 | |
| Octapharma USA, INC. | $20.00 | 2022 | |
| Celgene Corporation | $19.96 | 2019 | |
| Biotronik Nro, INC. | $19.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.52 | 2019 | |
| Providence Medical Technology, INC. | $16.80 | 2021 | |
| Abbott Laboratories | $15.09 | 2024 | Proclaim |
| Hikma Pharmaceuticals USA | $13.57 | 2021 | |
| Pacira Therapeutics, INC. | $13.53 | 2019 | |
| Antares Pharma, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.